PATENT CLAIM ANALYSIS

Application Number: 16012351
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-04
Patent Classification: ["514", "183000"]

Abstract:
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

Claim (Index 18):
The method of  claim 10 , further comprising obtaining the irinotecan liposome injection formulation by diluting a solution comprising about 5 mg irinotecan/mL to obtain a dose equivalent of 60-80 mg/m 2  in a volume of 500 mL prior to administration of the irinotecan liposome injection formulation.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 94.0
- Lexical Diversity: 1.22857
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14851111', '15241128', '14406776', '14812950', '14844500']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8300067816547216
- 35 USC 102 Novelty (BERT): 0.6293132191473654
- Combined Prediction Score: 0.8099374254039859
- Mean Citation Score: 580.9896340000001
- Max Citation Score: 688.93396
- Similarity Product: 495.23230435464376

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test